This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat
by Indrajit Bandyopadhyay
Merck KGaA (MKGAF) reports a mixed second-quarter with earnings declining year-over-year while sales remaining flat.
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are expected to drive sales in Q2. However, higher operating expense to support Bavencio and Mavenclad launch is expected to weigh on performance.
Juniper Inks Deal to be Acquired by Catalent, Shares Up
by Zacks Equity Research
Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y
by Zacks Equity Research
Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.
Merck KGaA's Tepotinib Gets Fast Track Designation in Japan
by Zacks Equity Research
Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.
Merck KGaA (MKGAF) Q4 Earnings Flat Y/Y, Sales Up
by Indrajit Bandyopadhyay
Merck KGaA (MKGAF) reports a mixed fourth-quarter with earnings remaining flat year-over-year while sales is up.
What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.
Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.
Roche MS Drug Ocrevus Gets Marketing Authorization in Europe
by Zacks Equity Research
Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.
Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study
by Zacks Equity Research
Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.
Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up
by Zacks Equity Research
Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.
Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat
by Zacks Equity Research
Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.
Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat
by Zacks Equity Research
Merck KGaA (MKGAF) reports a challenging third-quarter with earnings down year-over-year and sales remaining flat.
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.
Merck KGaA (MKGAF) Q2 Earnings Up Y/Y
by Indrajit Bandyopadhyay
Merck KGaA (MKGAF) reports second-quarter results with earnings rising year-over-year and sales registering organic growth.
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?
by Zacks Equity Research
Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase
by Zacks Equity Research
Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.
Merck KGaA (MKGAF) Q1 Earnings Down Y/Y, 2017 View Updated
by Indrajit Bandyopadhyay
The company???s first-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.28, compared to the year-ago figure of $1.50
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.
Is BioMarin (BMRN) Well Poised for Growth in 2017?
by Zacks Equity Research
We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.
Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
by Zacks Equity Research
Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.
BioMarin (BMRN) Raised to Buy: Should You Add the Stock?
by Zacks Equity Research
The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).